These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

143 related articles for article (PubMed ID: 20389302)

  • 1. Self-reported health-related quality of life is an independent predictor of chemotherapy treatment benefit and toxicity in women with advanced breast cancer.
    Lee CK; Stockler MR; Coates AS; Gebski V; Lord SJ; Simes RJ;
    Br J Cancer; 2010 Apr; 102(9):1341-7. PubMed ID: 20389302
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Prognostic value of quality-of-life scores during chemotherapy for advanced breast cancer. Australian New Zealand Breast Cancer Trials Group.
    Coates A; Gebski V; Signorini D; Murray P; McNeil D; Byrne M; Forbes JF
    J Clin Oncol; 1992 Dec; 10(12):1833-8. PubMed ID: 1453197
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Buparlisib plus fulvestrant versus placebo plus fulvestrant in postmenopausal, hormone receptor-positive, HER2-negative, advanced breast cancer (BELLE-2): a randomised, double-blind, placebo-controlled, phase 3 trial.
    Baselga J; Im SA; Iwata H; Cortés J; De Laurentiis M; Jiang Z; Arteaga CL; Jonat W; Clemons M; Ito Y; Awada A; Chia S; Jagiełło-Gruszfeld A; Pistilli B; Tseng LM; Hurvitz S; Masuda N; Takahashi M; Vuylsteke P; Hachemi S; Dharan B; Di Tomaso E; Urban P; Massacesi C; Campone M
    Lancet Oncol; 2017 Jul; 18(7):904-916. PubMed ID: 28576675
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Quality-of-life scores predict outcome in metastatic but not early breast cancer. International Breast Cancer Study Group.
    Coates AS; Hürny C; Peterson HF; Bernhard J; Castiglione-Gertsch M; Gelber RD; Goldhirsch A
    J Clin Oncol; 2000 Nov; 18(22):3768-74. PubMed ID: 11078489
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Polychemotherapy for early breast cancer: results from the international adjuvant breast cancer chemotherapy randomized trial.
    Adjuvant Breast Cancer Trials Collaborative Group
    J Natl Cancer Inst; 2007 Apr; 99(7):506-15. PubMed ID: 17405995
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Impact of adjuvant therapy on quality of life in women with node-positive operable breast cancer. International Breast Cancer Study Group.
    Hürny C; Bernhard J; Coates AS; Castiglione-Gertsch M; Peterson HF; Gelber RD; Forbes JF; Rudenstam CM; Simoncini E; Crivellari D; Goldhirsch A; Senn HJ
    Lancet; 1996 May; 347(9011):1279-84. PubMed ID: 8622502
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Identification and interpretation of clinical and quality of life prognostic factors for survival and response to treatment in first-line chemotherapy in advanced breast cancer.
    Kramer JA; Curran D; Piccart M; de Haes JC; Bruning P; Klijn J; Van Hoorebeeck I; Paridaens R
    Eur J Cancer; 2000 Aug; 36(12):1498-506. PubMed ID: 10930797
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Randomized trial of cyclophosphamide, methotrexate, and fluorouracil chemotherapy added to tamoxifen as adjuvant therapy in postmenopausal women with node-positive estrogen and/or progesterone receptor-positive breast cancer: a report of the National Cancer Institute of Canada Clinical Trials Group. Breast Cancer Site Group.
    Pritchard KI; Paterson AH; Fine S; Paul NA; Zee B; Shepherd LE; Abu-Zahra H; Ragaz J; Knowling M; Levine MN; Verma S; Perrault D; Walde PL; Bramwell VH; Poljicak M; Boyd N; Warr D; Norris BD; Bowman D; Armitage GR; Weizel H; Buckman RA
    J Clin Oncol; 1997 Jun; 15(6):2302-11. PubMed ID: 9196144
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Prognostic value of quality of life scores in a trial of chemotherapy with or without interferon in patients with metastatic malignant melanoma.
    Coates A; Thomson D; McLeod GR; Hersey P; Gill PG; Olver IN; Kefford R; Lowenthal RM; Beadle G; Walpole E
    Eur J Cancer; 1993; 29A(12):1731-4. PubMed ID: 8398303
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Prognostic factors in elderly women with metastatic breast cancer treated with tamoxifen: an analysis of patients entered on four prospective clinical trials.
    Dhodapkar MV; Ingle JN; Cha SS; Mailliard JA; Wieand HS
    Cancer; 1996 Feb; 77(4):683-90. PubMed ID: 8616760
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Concomitant chemoradiotherapy for patients with nonmetastatic breast carcinoma: side effects, quality of life, and organization.
    Macquart-Moulin G; Viens P; Genre D; Bouscary ML; Resbeut M; Gravis G; Camerlo J; Maraninchi D; Moatti JP
    Cancer; 1999 May; 85(10):2190-9. PubMed ID: 10326697
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Phase II trial of fulvestrant with metronomic capecitabine for postmenopausal women with hormone receptor-positive, HER2-negative metastatic breast cancer.
    Schwartzberg LS; Wang G; Somer BG; Blakely LJ; Wheeler BM; Walker MS; Stepanski EJ; Houts AC
    Clin Breast Cancer; 2014 Feb; 14(1):13-9. PubMed ID: 24268206
    [TBL] [Abstract][Full Text] [Related]  

  • 13. CDK4/6 inhibitor treatment for patients with hormone receptor-positive, HER2-negative, advanced or metastatic breast cancer: a US Food and Drug Administration pooled analysis.
    Gao JJ; Cheng J; Bloomquist E; Sanchez J; Wedam SB; Singh H; Amiri-Kordestani L; Ibrahim A; Sridhara R; Goldberg KB; Theoret MR; Kluetz PG; Blumenthal GM; Pazdur R; Beaver JA; Prowell TM
    Lancet Oncol; 2020 Feb; 21(2):250-260. PubMed ID: 31859246
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cyclophosphamide, methotrexate and fluorouracil (CMF) versus hormonal ablation with leuprorelin acetate as adjuvant treatment of node-positive, premenopausal breast cancer patients: preliminary results of the TABLE-study (Takeda Adjuvant Breast cancer study with Leuprorelin Acetate).
    Schmid P; Untch M; Wallwiener D; Kossé V; Bondar G; Vassiljev L; Tarutinov V; Kienle E; Lüftner D; Possinger K;
    Anticancer Res; 2002; 22(4):2325-32. PubMed ID: 12174922
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Defining clinical benefit in postmenopausal patients with breast cancer under second-line endocrine treatment: does quality of life matter?
    Bernhard J; Thürlimann B; Schmitz SF; Castiglione-Gertsch M; Cavalli F; Morant R; Fey MF; Bonnefoi H; Goldhirsch A; Hürny C
    J Clin Oncol; 1999 Jun; 17(6):1672-9. PubMed ID: 10561203
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Randomized trial of letrozole following tamoxifen as extended adjuvant therapy in receptor-positive breast cancer: updated findings from NCIC CTG MA.17.
    Goss PE; Ingle JN; Martino S; Robert NJ; Muss HB; Piccart MJ; Castiglione M; Tu D; Shepherd LE; Pritchard KI; Livingston RB; Davidson NE; Norton L; Perez EA; Abrams JS; Cameron DA; Palmer MJ; Pater JL
    J Natl Cancer Inst; 2005 Sep; 97(17):1262-71. PubMed ID: 16145047
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Identification of risk factors for toxicity in patients with hormone receptor-positive advanced breast cancer treated with bevacizumab plus letrozole: a CALGB 40503 (alliance) correlative study.
    Li D; McCall LM; Hahn OM; Hudis CA; Cohen HJ; Muss HB; Jatoi A; Lafky JM; Ballman KV; Winer EP; Tripathy D; Schneider B; Barry W; Dickler MN; Hurria A
    Breast Cancer Res Treat; 2018 Sep; 171(2):325-334. PubMed ID: 29789969
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Vascular-endothelial-growth-factor (VEGF) targeting therapies for endocrine refractory or resistant metastatic breast cancer.
    Wagner AD; Thomssen C; Haerting J; Unverzagt S
    Cochrane Database Syst Rev; 2012 Jul; (7):CD008941. PubMed ID: 22786517
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Burdens and benefits of adjuvant cyclophosphamide, methotrexate, and fluorouracil and tamoxifen for elderly patients with breast cancer: the International Breast Cancer Study Group Trial VII.
    Crivellari D; Bonetti M; Castiglione-Gertsch M; Gelber RD; Rudenstam CM; Thürlimann B; Price KN; Coates AS; Hürny C; Bernhard J; Lindtner J; Collins J; Senn HJ; Cavalli F; Forbes J; Gudgeon A; Simoncini E; Cortes-Funes H; Veronesi A; Fey M; Goldhirsch A
    J Clin Oncol; 2000 Apr; 18(7):1412-22. PubMed ID: 10735888
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Treatment of axillary lymph node-negative, estrogen receptor-negative breast cancer: updated findings from National Surgical Adjuvant Breast and Bowel Project clinical trials.
    Fisher B; Jeong JH; Anderson S; Wolmark N
    J Natl Cancer Inst; 2004 Dec; 96(24):1823-31. PubMed ID: 15601638
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.